Ocugen (NASDAQ:OCGN) had its target price raised by Cantor Fitzgerald from $1.00 to $4.00 in a report released on Wednesday morning, The Fly reports. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Their forecasts range from $4.50 to $11.00. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. OCGN has an Overall Score of 67. Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. OCGN Stock News Comes as JNJ Vaccine Remains on Pause. However, the Strong Buy consensus rating is backed with a $0.9 price target, which implies downside of 68% from current levels. Move your mouse over past months for details. This may be the next lithium giant to feed surging global battery demand for EVs! Analysts stock forecasts for Ocugen stock Firstly, across the board of Wallstreet analysts the general consensus is a Buy. Want to see which stocks are moving? The lighter blue line represents the stock's consensus price target. Press Release reported on 05/13/21 that Thinking about buying stock in Sundial Growers, P Over the past week, OCGN shares had nearly … For the coming years our community has positive and negative things to say abot the Ocugen Inc. stock. View our full suite of financial calendars and market data tables, all for free. Roth Capital raised their price target on shares of Ocugen from $9.00 to $10.00 and gave the stock a buy rating in a research note on Thursday, March 4th. Ocugen Inc has a Long-Term Technical rank of 100. HC Wainwright has the lowest price target set, forecasting a price of $4.50 for Ocugen in the next year. Prior to their COVID-19 vaccine developments, the companies average price target was around $0.98 a share. The average price target is $8.38, with a high forecast of $11.00 and a low forecast of $4.50. Their average twelve-month price target is $8.38, predicting that the stock has a possible downside of 2.73%. The stock price of Ocugen Inc (NASDAQ: OCGN) has received a price target increase by Chardan Capital from $0.70 to $13. To see all exchange delays and terms of use please see disclaimer. View the latest analyst ratings for OCGN. America! Sign-up to receive the latest news and ratings for OCGN and its competitors with Analyst As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Despite the day-on-day decline, that is still the stock’s strongest close since early February 2021. Why Ocugen Stock Is Tanking Today Shares of Ocugen (NASDAQ: OCGN) were tanking by 12.7% as of 11:16 a.m. EDT on Friday after falling as much as 20.6% earlier in the day. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen stock price hits two-month high. They currently have an overweight rating on the stock. This Little-Known Lithium Explorer May About to Rocket. HC Wainwright raised shares of Ocugen from a neutral rating to a buy rating and set a $4.50 price target for the company in a research report on Thursday, February 4th. The shares of Ocugen Inc (NASDAQ: OCGN) have received a $10 price target by Roth Capital. This means that trading over the last 200 trading days has placed the company in the upper half of stocks with 0% of the market … OCGN updated stock price target summary. Ocugen (NASDAQ:OCGN) had its price objective hoisted by Roth Capital from $1.00 to $8.00 in a report published on Wednesday, The Fly reports. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. The average 12 month price target from analysts is at $12.50 a share according to WSJ data. Ocugen (OCGN) Stock Price Predictions | Bharat Biotech Crisis & More Pressure On Biden! The average analyst price target of $12.50 implies that the stock has an … Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). 326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. If playback doesn't begin shortly, try restarting your device. PriceTargets.com does not provide financial advice and does not issue recommendations or offers to buy stock or Other companies that are similar to Ocugen include Fate Therapeutics, Denali Therapeutics, Halozyme Therapeutics, Vir Biotechnology, Adaptive Biotechnologies, China Biologic Products, Twist Bioscience, Beam Therapeutics, Kodiak Sciences, Allogene Therapeutics, Iovance Biotherapeutics, Ablynx, SpringWorks Therapeutics, Bavarian Nordic A/S and Relay Therapeutics. Receive a free world-class investing education from MarketBeat. Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Several other equities analysts have also issued reports on OCGN. © American Consumer News, LLC dba PriceTargets.com ® 2010-2021. The chart below shows how a company's share price and consensus price target have changed over time. A new-to-market sector is flying below the radar…and one stock has a major advantage that can help it capitalize on the sector’s forecasted 104% CAGR. Export data to Excel for your own analysis. They are not Tesla investors. Emergency Use Authorization (EUA) for COVID-19 vaccine Covaxin. Ocugen, Inc (OCGN) Stock! On the other hand, Ocugen's target price is what analysts think the stock is worth or could sell for in the future. Their average twelve-month price target is $8.38, suggesting a possible downside of 9.9%. The current price of Ocugen is the price at which Ocugen Inc is currently trading. The Newest Lithium Player Fueling the Green Revolution. sell any security. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. The target price of €2.00 compared with the current price of €5.69 for the stock indicates a negative potential of -64.875%. Equity ratings for Ocugen Inc are calculated daily … Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Time To Buy!! The stock’s price range for the 52-week period … A "buy" rating indicates that analysts believe OCGN will outperform the market and that investors should add to their positions of Ocugen. Ratings Network’s free daily newsletter. Ocugen Inc. (NASDAQ:OCGN) went up by 6.32% from its latest closing price compared to the recent 1-year high of $18.77. Ocugen (NASDAQ:OCGN) Price Target Increased to $8.00 by Analysts at Roth Capital. Learn about financial terms, types of investments, trading strategies and more. The average price target is $8.38, with a high forecast of $11.00 and a low forecast of $4.50. Ocugen currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Ocugen's current and average target prices are 8.23 and 0.90, respectively. And there's something that every cannabis investor needs to see... Get New Ocugen Analyst Ratings Delivered To Your Inbox. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Ocugen Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Please log in to your account or sign up in order to add this asset to your watchlist. As of May 04. 4 Wall Street analysts have issued ratings and price targets for Ocugen in the last 12 months. Ocugen is still up 280% year-to-date and 2,137% (21 times) in the past year. According to 4 Wall Street analysts that have issued a 1 year OCGN price target, the average OCGN price target is $7.38 , with the highest OCGN stock price forecast at $13.00 and the lowest OCGN stock price forecast at $1.00 . Ocugen aims to launch the two-dose vaccine for the U.S. market in the second quarter of 2021. And Roth Capital analyst Zegbeh Jallah assigned Ocugen a “Buy” rating. This small cap explorer may be sitting on one of the biggest lithium finds in No. Identify stocks that meet your criteria using seven unique stock screeners. 4 Wall Street analysts have issued 1-year target prices for Ocugen's stock. Get daily stock ideas top-performing Wall Street analysts. These factors prompted Cantor Fitzgerald analyst Kristen Kluska to raise her price target on Ocugen stock to $4, up from $1. Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. The stock's open price was 9.58.Ocugen has 53 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. OCGN: Get the latest Ocugen stock price and detailed information including OCGN news, historical charts and realtime prices. This rating has held steady since October 2020, when it changed from a Hold consensus rating. Our Accessibility Statement | Terms of Service | Do Not Sell My Information. Get short term trading ideas from the MarketBeat Idea Engine. The analyst also kept an overweight rating on the stock. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Fundamental company data provided by Zacks Investment Research. The following Wall Street analysts have issued research reports on Ocugen in the last twelve months: Cantor Fitzgerald, Chardan Capital, HC Wainwright, Roth Capital, and Zacks Investment Research. Cantor Fitzgerald has the highest price target set, predicting OCGN will reach $11.00 in the next twelve months. This price target is based on 4 analysts offering 12 month price targets for Ocugen in the last 3 months. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Delayed Data. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The average target price for the stock is $4.8, which implies a downside potential of nearly 30 percent. PriceTargets.com provides comprehensive coverage of stock ratings, including equities research analysts’ upgrades, downgrades, new coverage and price target We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. -3.17 / -20.22%. They currently have a buy rating on the stock. MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. PriceTargets.com keeps track of all major brokerages’ stock ratings and recommendations, including Goldman Sachs, JPMorgan Chase, Wells Fargo, Bank of America/Merrill Lynch, Citigroup, Morgan Stanley and many more. MUST WATCH! Overall, the consensus on the Street is that OCGN is a Strong Buy, based on 3 Buys and 1 Hold. This is a -4.07% down since the beginning of the trading day. Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. This suggests that the stock has a possible downside of 2.3%. 4 Wall Street analysts have set twelve-month price targets for Ocugen in the last year. Posted by Brenda Bartman on Feb 7th, 2021. You can opt out at any time. View the latest ratings for OCGN. Cantor Fitzgerald does not see either upside or downside right now … The average price target represents a -4.29% upside from the last price of $8.75. View the latest price targets for OCGN. Fundamental company data provided by Zacks Investment Research. Ocugen stock is selling for 9.19 as of the 8th of May 2021. What is OCGN's Price Target? Negative data or inability to secure an EUA (Emergency Use Authorisation) is a key downside risk to the stock from current levels.” Chadran’s Keay Nakae raised his target price to $13 from $0.70, although he cut his rating to ‘neutral’ from ‘overweight’. MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock. The stock has a consensus analyst rating of "Buy." 0.17. All rights reserved. The high price target for OCGN is $11.00 and the low price target for OCGN is $4.50. See what's happening in the market right now with MarketBeat's real-time news feed. Their average twelve-month price target is $8.38, predicting that the stock has a possible downside of 3.40%. To see all exchange delays and terms of use please see disclaimer. This is most likely a result of the stock… OCUGEN : Chardan Adjusts Price Target on Ocugen to $8 From $13, Maintains Neutral Rating Ever since that announcement, the stock has been on a tear, leaving Chardan analyst Keay Nakae's previous $0.70-per-share price target in the dust.. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Analysts might take a new look at the stock … changes. © American Consumer News, LLC dba MarketBeat® 2010-2021. Full legalization may change the investing world forever. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). The company is headquartered in Malvern, Pennsylvania. The company’s stock price has collected -4.74% of loss in the last five trading sessions. Investor Alert: The 2021 Cannabis "Legalization Boom". This price target is based on 4 analysts offering 12 month price targets for Ocugen in the last 3 months. Find out what this means to you and get the rest of the rankings on OCGN! MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. But investors in this company could end up really happy if the Lithium Megatrend continues.document.write(''); View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Ocugen stock has a median target price of $1, which is a premium of 24 percent over its closing prices on Dec. 22. See Full OCGN Report . You can opt out at any time. The average 12-month price target from four analysts that have issued an Ocugen share price forecast is $4.80 per share, with a high estimate of $10 per share and a low of $0.70 per share. 4 Wall Street analysts have issued ratings and price targets for Ocugen in the last 12 months. OCUGEN INC OCGN STOCK CHART ANALYSIS | NEW PRICE TARGET BY ANALYSIS RATINGS OF $8 ALMOST REACHED ! Ocugen's physical mailing address is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. The current consensus among 4 contributing investment analysts is to buy stock in Ocugen. The high price target for OCGN is $11.00 and the low price target for OCGN is $4.50. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. OCUGEN : Chardan Adjusts Price Target on Ocugen to $8 From $13, Maintains Neutral Rating Three of the analysts recommend the stock as a buy, with one rating it a hold. However, Chardan Capital downgraded the stock to “Neutral” from “Buy” based on the recent stock price surge. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. On average, they anticipate Ocugen's share price to reach $8.38 in the next year. Instead, the bigger issue was probably that the company still hasn't made tangible progress toward securing U.S. Presently, Ocugen Inc. shares are logging -53.38% during the 52-week period from high price, and 5047.06% higher than the lowest price point for the same timeframe. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Buy.". All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103. The company's listed phone number is 484-328-4701 and its investor relations email address is [email protected] The official website for Ocugen is ocugen.com. Shares of Ocugen - a gene therapy firm that aims to cure blindness and is also working on a new coronavirus vaccine - pulled back by 3.9% to finish Wednesday at US$11.21. - YouTube. HC Wainwright reiterated a hold rating on shares of Ocugen in a research note on Monday, … Today’s Change. Looking for new stock ideas? Ocugen Inc (NASDAQ:OCGN) Ocugen Inc. 12.50. In recent trading, shares of Ocugen Inc (Symbol: OCGN) have crossed above the average analyst 12-month target price of $12.50, changing hands for $12.67/share. The dark blue line represents the company's actual price. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Start Your Risk-Free Trial Subscription Here, The Container Store Has What Every Growth Stocks Needs, Don’t Rush To Buy Walmart, Extra Low Prices Are On The Way, Legal Issues Behind It, IBIO Stock May Be a Long Play For Risk-Tolerant Investors, Steel Producers Extend Their One-Year Gains On Strong Demand, Lumentum Stock Providing Opportunistic Pullbacks, 3 Stocks to Play the Shopping Mall Revival, Snowflake (NYSE: SNOW) Starts To Look Hot, 7 Cyclical Stocks That Can Help You Play Defense, 7 Stocks That Could Benefit From a Capital Gains Tax Hike, 7 Forever Stocks That Are Never Bad to Buy, 7 Stocks That Still Have Upside For Investors to Buy, 7 Precious Metals Stocks That Will Keep Your Portfolio On Trend, 7 Bellwether Stocks Signaling a Return to Normal, 7 Electric Vehicle (EV) Stocks That Are Ready to Rebound, 7 Sports Betting Stocks That Will Shine Beyond March Madness, 7 Stocks That Cathie Wood is Buying And You Should Too, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, Receive Analysts' Upgrades and Downgrades Daily. The company has an average price target of $2.55. View which stocks are hot on social media with MarketBeat's trending stocks report. Learn more about MarketBeat. HUGE Potential, Price Target! Ad - Prosper Trading Academy 16 Scott B … The average price target represents a -3.40% upside from the last price of $8.67.
City Of Liverpool Fc League Table, What Happened Mike Parry, Hôtel Du Collectionneur, Restaurant, Cara Menambah Memori Iphone, Cbdc How To Buy, Tesla Etf Vanguard, Csdhl Standings 2020 -2021, When Is Summer Break 2021 Usa,
